These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

532 related items for PubMed ID: 31307383

  • 1. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
    Stark C, Stark R, Limberg N, Rodrigues J, Cordato D, Schwartz R, Jukic R.
    J Headache Pain; 2019 Jul 15; 20(1):81. PubMed ID: 31307383
    [Abstract] [Full Text] [Related]

  • 2. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
    Aurora SK, Dodick DW, Diener HC, DeGryse RE, Turkel CC, Lipton RB, Silberstein SD.
    Acta Neurol Scand; 2014 Jan 15; 129(1):61-70. PubMed ID: 24107267
    [Abstract] [Full Text] [Related]

  • 3. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK, Sadowsky CH, Martinez WC, Zuniga JA, Poulette A.
    Headache; 2012 Sep 15; 52(8):1219-25. PubMed ID: 22607530
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of onabotulinumtoxinA (BOTOX®) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data.
    Lanteri-Minet M, Ducros A, Francois C, Olewinska E, Nikodem M, Dupont-Benjamin L.
    Cephalalgia; 2022 Dec 15; 42(14):1543-1564. PubMed ID: 36081276
    [Abstract] [Full Text] [Related]

  • 5. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
    Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A.
    J Headache Pain; 2018 Feb 05; 19(1):13. PubMed ID: 29404713
    [Abstract] [Full Text] [Related]

  • 6. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
    Young WB, Ivan Lopez J, Rothrock JF, Orejudos A, Manack Adams A, Lipton RB, Blumenfeld AM.
    J Headache Pain; 2019 Feb 01; 20(1):12. PubMed ID: 30709333
    [Abstract] [Full Text] [Related]

  • 7. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials.
    Silberstein SD, Diener HC, Dodick DW, Sommer K, Lipton RB.
    Headache; 2024 Feb 01; 64(7):838-848. PubMed ID: 38982666
    [Abstract] [Full Text] [Related]

  • 8. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.
    Headache; 2011 Oct 01; 51(9):1358-73. PubMed ID: 21883197
    [Abstract] [Full Text] [Related]

  • 9. FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
    Rothrock JF, Adams AM, Lipton RB, Silberstein SD, Jo E, Zhao X, Blumenfeld AM, FORWARD Study investigative group.
    Headache; 2019 Nov 01; 59(10):1700-1713. PubMed ID: 31559634
    [Abstract] [Full Text] [Related]

  • 10. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW.
    J Neurol Sci; 2013 Aug 15; 331(1-2):48-56. PubMed ID: 23790235
    [Abstract] [Full Text] [Related]

  • 11. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study.
    Ahmed F, Gaul C, García-Moncó JC, Sommer K, Martelletti P, REPOSE Principal Investigators.
    J Headache Pain; 2019 Mar 07; 20(1):26. PubMed ID: 30845917
    [Abstract] [Full Text] [Related]

  • 12. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group.
    Headache; 2010 Jun 07; 50(6):921-36. PubMed ID: 20487038
    [Abstract] [Full Text] [Related]

  • 13. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.
    Negro A, Curto M, Lionetto L, Martelletti P.
    J Headache Pain; 2015 Jun 07; 17():1. PubMed ID: 26792662
    [Abstract] [Full Text] [Related]

  • 14. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
    Lipton RB, Varon SF, Grosberg B, McAllister PJ, Freitag F, Aurora SK, Dodick DW, Silberstein SD, Diener HC, DeGryse RE, Nolan ME, Turkel CC.
    Neurology; 2011 Oct 11; 77(15):1465-72. PubMed ID: 21956721
    [Abstract] [Full Text] [Related]

  • 15. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
    Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, Turkel CC.
    J Neurol Neurosurg Psychiatry; 2015 Sep 11; 86(9):996-1001. PubMed ID: 25500317
    [Abstract] [Full Text] [Related]

  • 16. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
    Torres-Ferrus M, Gallardo VJ, Alpuente A, Pozo-Rosich P.
    J Headache Pain; 2020 Jul 11; 21(1):88. PubMed ID: 32652924
    [Abstract] [Full Text] [Related]

  • 17. OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.
    Frampton JE.
    Drugs; 2012 Apr 16; 72(6):825-45. PubMed ID: 22468643
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
    Blumenfeld AM, Patel AT, Turner IM, Mullin KB, Manack Adams A, Rothrock JF.
    J Prim Care Community Health; 2020 Apr 16; 11():2150132720959936. PubMed ID: 32985341
    [Abstract] [Full Text] [Related]

  • 20. OnabotulinumtoxinA Reduces Health Resource Utilization in Chronic Migraine: PREDICT Study.
    Becker WJ, Boudreau G, Finkelstein I, Graboski C, Ong M, Christie S, Sommer K, Bhogal M, Davidovic G.
    Can J Neurol Sci; 2023 May 16; 50(3):418-427. PubMed ID: 35466897
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.